• Prescriptions
  • Telehealth
  • Free Shipping
Create an account and get a online doctor visit
MENU ×
Main Menu ×

All Categories


  •  
  •  

Tri-Sprintec

$

Free & Easy Home Delivery

Introductory Offer: $20 off your first order!



 (2-5 business days)
Total $ 0.00

More about Tri-Sprintec

Tri-Sprintec® (norgestimate and ethinyl estradiol tablets USP) is a combination oral contraceptive containing the progestational compound norgestimate, USP and the estrogenic compound ethinyl estradiol, USP.It is used to prevent pregnancy. It is used to treat pimples (acne). It may be given to you for other reasons. Talk with the doctor.
Use Tri-Sprintec (ethinyl estradiol and norgestimate) as ordered by your doctor. Read all information given to you. Follow all instructions closely. Follow how to use as you have been told by the doctor or read the package insert. Take Tri-Sprintec (ethinyl estradiol and norgestimate) at the same time of day. Take with or without food. Take with food if it causes an upset stomach. If you also take colesevelam, take it at least 4 hours after you take Tri-Sprintec (ethinyl estradiol and norgestimate). Do not skip doses, even if you do not have sex very often. If you throw up or have diarrhea, Tri-Sprintec (ethinyl estradiol and norgestimate) may not work as well to prevent pregnancy. Use an extra form of birth control, like condoms, until you check with your doctor. If you miss 2 periods in a row, take a pregnancy test before starting a new cycle.
The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling: Serious cardiovascular events and stroke [see BOX WARNING and WARNINGS AND PRECAUTIONS] Vascular events [see WARNINGS AND PRECAUTIONS] Liver disease [see WARNINGS AND PRECAUTIONS] Adverse reactions commonly reported by COC users are: Irregular uterine bleeding Nausea Breast tenderness Headache Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of Tri-Sprintec was evaluated in 4,826 healthy women of child-bearing potential who participated in 6 clinical trials and received at least 1 dose of Tri-Sprintec for contraception. Two trials were randomized active-controlled trials and 4 were uncontrolled open-label trials. In 3 trials, subjects were followed for up to 24 cycles; in 2 trials, subjects were followed for up to 12 cycles; and in 1 trial, subjects were followed for up to 6 cycles. Common Adverse Reactions (= 2% Of Subjects) The most common adverse reactions reported by at least 2% of the 4,826 women were the following in order of decreasing incidence: headache/migraine (33.6%), breast issues (including breast pain, enlargement, and discharge) (8%), vaginal infection (7.1%), abdominal/gastrointestinal pain (5.6%), mood disorders (including mood alteration and depression) (3.8%), genital discharge (3.2%), and changes in weight (including weight fluctuation, increased or decreased) (2.5%). Adverse Reactions Leading To Study Discontinuation Over the trials, between 9 to 27% of subjects discontinued the trial due to an adverse reaction. The most common adverse reactions (=1%) leading to discontinuation were: metrorrhagia (4.3%), nausea/vomiting (2.8%), headache/migraine (2.4%), mood disorders (including depression and mood altered) (1.1%), and weight increased (1.1%). Serious Adverse Reactions breast cancer (1 subject), carcinoma of the cervix in situ (1 subject), hypertension (1 subject), and migraine (2 subjects). Postmarketing Experience The following additional adverse drug reactions have been reported from worldwide postmarketing experience with norgestimate/ethinyl estradiol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Infections and Infestations: Urinary tract infection; Neoplasms Benign, Malignant and Unspecified (Incl. Cysts and Polyps): Breast cancer, benign breast neoplasm, hepatic adenoma, focal nodular hyperplasia, breast cyst; Immune System Disorders: Hypersensitivity; Metabolism and Nutrition Disorders: Dyslipidemia; Psychiatric Disorders: Anxiety, insomnia; Nervous System Disorders: Syncope, convulsion, paresthesia, dizziness; Eye Disorders: Visual impairment, dry eye, contact lens intolerance; Ear and Labyrinth Disorders: Vertigo; Cardiac Disorders: Tachycardia, palpitations; Vascular Events: Deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, hot flush; Arterial Events: Arterial thromboembolism, myocardial infarction, cerebrovascular accident; Respiratory, Thoracic and Mediastinal Disorders: Dyspnea; Gastrointestinal Disorders: Pancreatitis, abdominal distension, diarrhea, constipation; Hepatobiliary Disorders: Hepatitis; Skin and Subcutaneous Tissue Disorders: Angioedema, erythema nodosum, hirsutism, night sweats, hyperhidrosis, photosensitivity reaction, urticaria, pruritus, acne; Musculoskeletal, Connective Tissue, and Bone Disorders: Muscle spasms, pain in extremity, myalgia, back pain; Reproductive System and Breast Disorders: Ovarian cyst, suppressed lactation, vulvovaginal dryness; General Disorders and Administration Site Conditions: Chest pain, asthenic conditions.
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. PROTECT FROM LIGHT.
Consult the labeling of concurrently used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. No drug-drug interaction studies were conducted with Tri-Sprintec. Effects Of Other Drugs On Combined Oral Contraceptives Substances Decreasing The Plasma Concentrations Of COCs: Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John’s wort. Interactions between hormonal contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. Colesevelam Colesevelam, a bile acid sequestrant, given together with a COC, has been shown to significantly decrease the AUC of EE. The drug interaction between the contraceptive and colesevelam was decreased when the two drug products were given 4 hours apart. Substances Increasing The Plasma Concentrations Of COCs: Co-administration of atorvastatin or rosuvastatin and certain COCs containing ethinyl estradiol (EE) increase AUC values for EE by approximately 20 to 25%. Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Protease Inhibitors And Nonnucleoside Reverse Transcriptase Inhibitors: Significant changes (increase or decrease) in the plasma concentrations of estrogen and/or progestin have been noted in some cases of co-administration with HIV protease inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir] or increase [e.g., indinavir and atazanavir/ritonavir])/HCV protease inhibitors (decrease [e.g., boceprevir and telaprevir]) or with non-nucleoside reverse transcriptase inhibitors (decrease [e.g., nevirapine] or increase [e.g., etravirine]). Effects Of Combined Oral Contraceptives On Other Drugs COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. COCs have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. Significant decrease in plasma concentration of lamotrigine has been shown, likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because the serum concentration of thyroid-binding globulin increases with use of COCs. Interference With Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins.
There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.
Free & Easy Home Delivery

Introductory Offer: $20 off your first order!



 (2-5 business days)
Total $ 0.00

Frequently Asked Questions

We've compiled a list of commonly asked questions for your convenience. If you are unable to find the answer to your question, please contact us for further assistance. It's just one more way UPRx prioritizes your self-care.


If you are one of half of the US population who benefits from taking prescription drugs, then UPRx is for you. We offer cash medication so you can…

• Bypass high insurance copays.
• Order with complete discretion.
• Purchase without insurance policy limitations and restrictions.
• Have access to lower priced medications
• Order your medication without insurance
• Avoid the hassle of going to the pharmacy to fill your prescriptions.

If any of the above sound as awesome to you as they do to us, we can safely say that UPRx is the alternative for you.
In order to fulfill your order we will need a corresponding prescription. However, if you don’t already have one we can help you with that! We have partnered with a third-party Telehealth company, providing online consultations with US licensed doctors, for a $5 fee.
We make it easy! All we require is contact information for your pharmacy or doctor’s office, and we will take care of transferring your prescription over for you. If you do not have an existing prescription, you can talk to one of our online physicians now and they can submit a prescription directly into our system for you.
UPRx.com offers both generic and brand-name prescription medications. The generic versions are generally significantly cheaper than the brand name version of a drug. However, please consult with your doctor to find out which variation of any specific drug is best for you.
With the exception of our products’ pricing and our third- party Telehealth service, the use of our website and services are completely cost-free.
After your order is placed, UPRx will retrieve your valid prescription from your doctor or pharmacy. Once the prescription is confirmed as authorized and corresponding to your order, our participating pharmacy begins to process your order. Depending on the specific drug and location, we can ship out some products as soon as same day, and we commit to shipping out all products within 48 hours of verifying your prescription.
Our site does not support insurance at this time, as we are focusing our efforts on getting you the best cash price. You may not know this, but there are some instances where it’s significantly cheaper to pay cash for a medication rather than to order it through your insurer’s pharmacy benefits program. Here at UPRx, we cut out the middleman and do the negotiating for you- providing you with the same drugs, for less pay.
Nothing should stand in the way of you getting the drugs you need to feel and perform your best. UPRx orders arrive in discreet packaging, because your health is personal, and should remain that way.
UPRx operates under strict HIPAA compliance laws and regulations to ensure that your privacy is paramount.
When UPRx obtains your medical information while acting on your behalf, we will maintain the privacy and security of that information in accordance with the standards of the HIPAA security regulations. Additionally, UPRx is fully registered and operates in multiple locations across the United States of America. Our partner pharmacy, Apogee BioPharm, is licensed and operated in all 50 states and territories. At UPRx we are committed to only purchasing locally sourced items and products.

Talk to a Pharmacist Now

Get answers to all your drug related questions.